Analysts expect that Eyenovia Inc (NASDAQ:EYEN) will post earnings per share (EPS) of ($0.44) for the current quarter, according to Zacks. Zero analysts have provided estimates for Eyenovia’s earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.46). Eyenovia reported earnings of ($0.84) per share during the same quarter last year, which suggests a positive year over year growth rate of 47.6%. The business is expected to report its next quarterly earnings report on Monday, April 1st.

According to Zacks, analysts expect that Eyenovia will report full-year earnings of ($1.69) per share for the current financial year, with EPS estimates ranging from ($1.78) to ($1.62). For the next financial year, analysts expect that the company will post earnings of ($1.37) per share, with EPS estimates ranging from ($1.55) to ($1.14). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Eyenovia.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.43) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.43).

EYEN has been the topic of a number of recent analyst reports. HC Wainwright initiated coverage on shares of Eyenovia in a research report on Tuesday, October 9th. They issued a “buy” rating and a $12.00 target price on the stock. Zacks Investment Research raised shares of Eyenovia from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a report on Friday, August 17th. Finally, ValuEngine upgraded shares of Eyenovia from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Five research analysts have rated the stock with a buy rating, Eyenovia presently has an average rating of “Buy” and an average price target of $17.63.

Eyenovia stock remained flat at $$3.05 during mid-day trading on Friday. 852 shares of the company’s stock were exchanged, compared to its average volume of 26,870. Eyenovia has a 12 month low of $2.64 and a 12 month high of $10.74. The firm has a market cap of $30.77 million and a price-to-earnings ratio of -1.39.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EYEN. Fairpointe Capital LLC acquired a new position in shares of Eyenovia during the second quarter worth $313,000. Millennium Management LLC acquired a new position in shares of Eyenovia during the first quarter worth $2,525,000. Finally, Uniplan Investment Counsel Inc. raised its holdings in Eyenovia by 11.8% in the third quarter. Uniplan Investment Counsel Inc. now owns 385,624 shares of the company’s stock valued at $1,550,000 after acquiring an additional 40,624 shares in the last quarter. Institutional investors own 11.61% of the company’s stock.

About Eyenovia

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

Read More: Bear Market

Get a free copy of the Zacks research report on Eyenovia (EYEN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with's FREE daily email newsletter.